WO1999055899A1 - Methodes de transduction de molecules de fusion - Google Patents

Methodes de transduction de molecules de fusion Download PDF

Info

Publication number
WO1999055899A1
WO1999055899A1 PCT/US1999/009028 US9909028W WO9955899A1 WO 1999055899 A1 WO1999055899 A1 WO 1999055899A1 US 9909028 W US9909028 W US 9909028W WO 9955899 A1 WO9955899 A1 WO 9955899A1
Authority
WO
WIPO (PCT)
Prior art keywords
fusion
protein
misfolded
fusion protein
molecule
Prior art date
Application number
PCT/US1999/009028
Other languages
English (en)
Other versions
WO1999055899A9 (fr
Inventor
Steven F. Dowdy
Original Assignee
Washington University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University filed Critical Washington University
Priority to CA002330560A priority Critical patent/CA2330560A1/fr
Priority to JP2000546042A priority patent/JP2002512808A/ja
Priority to EP99918838A priority patent/EP1073763A4/fr
Priority to AU36658/99A priority patent/AU3665899A/en
Publication of WO1999055899A1 publication Critical patent/WO1999055899A1/fr
Publication of WO1999055899A9 publication Critical patent/WO1999055899A9/fr
Priority to AU2003244303A priority patent/AU2003244303A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the present invention relates to highly efficient methods for transducing fusion molecules into cells or groups of cells.
  • the present methods have a variety of uses including transducing therapeutic fusion molecules into cells with high efficiency.
  • one standard method involves making cell holes and then transferring the nucleic acid through the holes e.g., by diffusion or along an imposed gradient.
  • the holes can be made by a variety of means such as physical penetration. Particular examples of such transfer methods have been disclosed. See e.g., Cockett, et al., Bio/Technology 8:662 (1990); Ausubel et al., supra; and Sambrook et al., supra.
  • nucleic acid transfer methods employ a bacteriophage or a virus to introduce the nucleic acid into cells by infection methods sometimes referred to as “transformation” or “transfection” methods. Once inside the target cell, the nucleic acid is typically expressed as part of the bacteriophage or virus lytic cycle. See e.g., Ausubel et al., infra; and Sambrook et al., infra.
  • nucleic acid over-expression e.g., nucleic acid over-expression, non-uniformity in levels of expressed protein, and low percentage of cells targeted by the methods. See e.g., Chen et al. Mol. Cell Biol. 7, 2745-2752 (1987). Friedman, T. Nat. Gene 2:93 (1992). Bar-Sagi, D. Meth. Enzy. 255,436-442 (1995).
  • pharmacologically relevant peptidyl mimetics and/or proteins have a size constraint problem that limits bioavailability when in excess of about 1 kDa.
  • transduction For example, one specific approach has attempted to transport proteins into cells by genetically fusing the proteins to specified transducing proteins.
  • the transducing proteins have been reported to carry the resulting fusion molecules into target cells by a process referred to as protein "transduction".
  • protein "transduction" See e.g., Frankel, A.D. and CO. Pabo (1988) Cell 55:1189; Fawell, S. et al. (1994) PNAS (USA) 91 : 664; Chen, L.L. et al. Anal. Biochem., 227:168 (1995); U.S. Pat. No. 5,652,122.; and PCT WO/04686.
  • the prior transduction methods have been associated with significant problems that have negatively impacted widespread use of the methods.
  • prior transduction methods are usually optimized to maintain fusion proteins in a native confirmation. Such methods can be complicated by attempts to maintain that native confirmation during use or storage of the fusion protein.
  • the present invention features highly efficient methods for transducing a fusion molecule into cells or groups of cells.
  • the methods generally include misfolding the fusion molecule and contacting the misfolded fusion molecule to the cells under conditions sufficient to transduce the misfolded fusion protein. Further provided are misfolded fusion molecules and methods for making same.
  • the present invention has a variety of uses including providing highly efficient transduction of therapeutic fusion molecules in vitro or in vivo.
  • misfolded fusion molecules can be transduced into cells much more effectively than native fusion molecules. More particularly, it has been found that a misfolded fusion molecule can transduce by as much as about one to three orders of magnitude more efficiently than the same fusion molecule in its native state (conformation).
  • a fusion molecule is "misfolded" in accord with this invention if it has been at least partially denatured and refolded and has decreased biochemical and/or biological activity as described herein.
  • the present invention can be used to increase transduction of a wide spectrum of fusion molecules.
  • the present methods can be used to lower an effective amount of a therapeutic fusion molecule by as much as about 2, 3, 5, 10, 50 or 100-fold or more compared to the effective amount required by the prior transduction methods, while achieving about the same degree of protein transduction, (e.g., number of molecules transduced per cell).
  • the lower effective amount does not impact the therapeutic activity of the fusion molecule in the transduced cells. That is, the present invention affords the same or nearly the same therapeutic activity in the transduced cells even when substantially lower amounts of the fusion molecule are used.
  • the invention achieves these objectives by misfolding the fusion molecule, thereby significantly boosting the transduction efficiency.
  • the present invention particularly enhances the transduction efficiency of large therapeutic fusion molecules such as those comprising one or more full-length proteins.
  • the present invention features transduction methods that are not limited to use of any particular fusion molecule, target cell or group of such cells.
  • any fusion molecule that has been misfolded in accord with this invention can be used to transduce a wide variety of cells in vitro or in vivo.
  • a fusion molecule can be misfolded in accord with this invention by one or a combination of strategies.
  • the fusion molecule can be misfolded by exposing the molecule to a first condition that is sufficient to partially or completely unfold (i.e., denature) the fusion molecule.
  • the denatured molecule is then further exposed to a second condition that is conducive to misfolding the fusion molecule.
  • the misfolded fusion molecule can be provided by one or more methods.
  • the first condition for denaturing the fusion molecule comprises contacting the fusion molecule with one or more protein denaturing agents.
  • the fusion molecule is present in its native or near-native conformation prior to exposure to the first condition.
  • the native or near-native fusion molecule is energetically stable and has, at least in theory, a low Gibbs free energy ( ⁇ G) in relation to the misfolded fusion molecule.
  • a suitable denaturant is selected to provide partial or complete denaturation of the fusion molecule.
  • Compositions and conditions that denature proteins are known to those in the art (see below). That is, the denaturing agent is typically selected to disrupt intramolecular bonds such as hydrogen and ionic bonds which themselves contribute to the secondary, tertiary or quarternary structure that the protein conforms to in solutions or buffers that are composed of physiological concentrations of salts, and other components, "physiological" being defined as a solvent composition that mimics in certain respects the natural solvent for proteins and polypeptides, namely the cell cytoplasm, blood, plasma and interstitial fluids.
  • the denaturing agent usually will not have substantial capacity to bind the fusion molecule, although such a denaturing agent can be used if it can be substantially separated from the denatured fusion molecule during purification.
  • Illustrative denaturing agents include at least one of an organic compound, a salt, a detergent, temperature or sound.
  • Illustrative are solutions that increase the Gibbs free energy ( ⁇ G) of the denatured fusion molecule by at least about 2 to 100 fold up to about 1000 fold or more compared to the Gibbs free energy of the native or near-native fusion molecule.
  • Preferred are solutions that significantly reduce or eliminate presence of the denaturing agents contacting the denatured molecule. More preferred aqueous solutions and particularly aqueous buffers such as those disclosed herein.
  • shock misfolding
  • the denatured fusion molecule is subjected to the second condition to form the misfolded fusion molecule.
  • that second condition is achieved by contacting the denatured molecule with an aqueous buffer (or more than one aqueous buffer if desired) sufficient to form the misfolded fusion molecule.
  • the contact can be suitably accomplished by a variety manipulations.
  • the denatured molecule can be applied to at least one chromatographic implementation.
  • the denatured molecule can be precipitated and then suspended into the aqueous buffer, or the denatured molecule can be filtered into the aqueous buffer.
  • one or more suitable eluting solutions are used.
  • those eluting solutions include or consist of the aqueous buffer.
  • Preferred eluting solutions are usually capable of releasing the fusion molecule (denatured or misfolded) from the chromatographic implementation used.
  • Manipulations that effectuate rapid desalting of the denatured fusion molecule, from the denaturing solution into an aqueous solution, e.g., by use of an appropriate chromatographic implementation, are particularly preferred for many applications.
  • the second condition is preferably selected to enhance the energetic instability of the denatured fusion molecule sufficient to form the misfolded fusion molecule into an aqueous buffer.
  • manipulations which are not optimized to substantially increase that instability are not usually preferred.
  • the contact between the denatured fusion molecule and the aqueous buffer can be accomplished by diluting the denatured fusion molecule into the aqueous buffer.
  • the dilution will be conducted in a ratio of between about 1 :10 (v/v) to 1 : 100,000 (v/v) or more depending on intended use.
  • the diluted (and misfolded) fusion molecule can be concentrated if desired by several conventional means such as membrane filtration or precipitation.
  • the present invention also features substantially pure preparations of misfolded fusion molecules that are suitable for a variety of uses including pharmaceutical or research use.
  • the misfolded fusion molecule is provided as a sterile composition which can include other additives as desired.
  • the misfolded fusion molecule may include one or more of the denaturing agents to enhance or maintain the misfolding, e.g., during storage.
  • the misfolded fusion molecule may include one or more stabilizing agents such as those known to be useful in the stabilization of proteins such as certain albumins, glycols, and sulfoxides.
  • transduction efficiency can be increased by up to about 2, 5, 10, 20, 50, 100, or 200 fold or more when compared to transduction with a suitable control molecule.
  • a preferred control molecule is the native fusion molecule, i.e. the fusion molecule that has not been treated to produce a misfolded, higher energy confirmation.
  • the present transduction methods are thus much more efficient than most prior transduction methods using native or near-native fusion molecules.
  • the enhanced transduction efficiency is evidenced by several parameters such as transduction rate and biological activity of transduced fusion protein.
  • the present methods provide highly efficient transduction of a variety of fusion molecules including fusion proteins and particularly large fusion proteins such as those potentially exhibiting therapeutic activity.
  • Lower effective amounts of the misfolded fusion molecules can be used to transduce cells or groups of cells, thereby significantly reducing or eliminating toxicity to the transduced cells.
  • the transduction methods described herein provide for transduction of fusion proteins, the size of which varies over a large range, including large proteins e.g. proteins having a molecular weight of about 5, 10, 20, 30, 40, 50, 100, 200, 300, 400 or 500 kDa or more.
  • Transduction of smaller fusion proteins is also readily accomplished by the present methods.
  • most prior transduction methods are optimized to transduce only the smaller fusion proteins. Widespread use of the prior methods has therefore been constrained by the size of the protein to be transduced. In particular, it has been difficult to transduce many therapeutic proteins and particularly large therapeutic proteins by the prior transduction methods.
  • the present invention avoids the need to miniaturize important protein domains (e.g., active or contact sites).
  • Prior methods generally have been limited to transducing miniaturized protein domains (fragments) and/or peptidyl mimetics into desired target cells.
  • protein domains can be large, sometimes exceeding about 15 up to 500 kDa or more in size.
  • the present invention thus overcomes such limitations of prior practice and provides methods for the efficient transduction of very large (and intact) proteins into cells. Additionally, cost and time associated with miniaturizing the protein domains is minimized or even avoided by the present invention.
  • the methods of the invention also positively impact purification and yields of the fusion molecules.
  • preferred methods include use of one or more denaturing agents to purify fusion proteins from cell components which naturally accompany it.
  • denaturing agents helps to free the fusion protein from the cell components, such as denatured and insoluble proteins that generally comprise the bulk of recombinant proteins and often present in bacterial inclusion bodies, thereby increasing both purity and yield substantially.
  • An illustrative preparative strategy according to the present invention involves expressing a desired fusion protein in host cells and isolating that fusion protein from fractions obtained from those cells. Isolation of the fusion proteins from the fractions and particularly insoluble fractions, has several advantages including protecting the misfolded fusion protein from degradation by host cell proteases. Significantly, preferred use of denaturing agents to prepare misfolded fusion proteins helps avoid time-consuming and costly protein renaturation techniques.
  • the methods of the invention also are generally flexible and can be tailored to provide quantities of a misfolded fusion molecule as needed. Specific methods include preparing fusion proteins in amounts ranging over a large scale (i.e., from microgram to gram to kilogram quantities) from a variety of implementations including roller bottles, spinner flasks, tissue culture plates, bioreactor, or a fermentor. The large-scale fusion protein preparation can then be misfolded according to any of the methods described herein.
  • the methods of the invention can be used to enhance transduction of a desired fusion molecule into target cells or groups of such cells. Accordingly, preparation and use of large amounts of the fusion molecule can be avoided if desired. This feature is particularly useful in situations where a given fusion molecule is difficult to prepare, or where large amounts of the fusion molecule are damaging to target cells in vitro or in vivo.
  • the present methods are also useful for producing misfolded fusion molecules in large quantities, e.g., to provide the fusion molecule as one component of a kit suitable for medical, research, home or commercial use. Further, it is useful to have methods of producing certain misfolded fusion molecules on a large-scale, e.g., to simplify structural analysis of the fusion molecule, to assist in the kinetic analysis of transduction, as well as for further purification and/or testing if desired.
  • the misfolded fusion molecules of this invention have a variety of additional uses including delivering a tag (marker) such as fluorescent, phosphorescent or immunological tag to a cell or group of cells.
  • a tag such as fluorescent, phosphorescent or immunological tag
  • the misfolded fusion molecules can be used to deliver a specified activity to the cells such as therapeutic activity.
  • the misfolded fusion molecules can be used in vitro or in vivo as needed.
  • therapeutic activity examples include delivery of therapeutic molecules including one or more radionuclides or cyto toxic drugs.
  • Illustrative fusion molecules generally include a transduction domain covalently linked to one or more desired molecules.
  • Preferred fusion molecules generally include a transduction domain and an amino acid sequence covalently linked as a genetic in-frame fusion protein.
  • the fusion protein will be made by standard genetic manipulations although in some cases it will be useful to make certain fusion molecules by chemical cross-linking as discussed below.
  • the molecular weight of the fusion molecule can be up to about 50 to 500 kD or more as estimated by SDS-PAGE gel electrophoresis or sedimentation centrifugation.
  • transduction domains include TAT, Antp, or specified transducing portions thereof such as the TAT basic region. Also contemplated are transduction domains comprising synthetic peptides. See e.g., Frankel, A.D. and Pabo, CO., supra; Falwell, S., et al. supra; Chen, et al. supra; U.S. Pat. Nos. 5,652,122 and PCT WO/04686.
  • misfolded fusion molecules of this invention are preferably used to transduce desired cells or groups of such cells including tissue and organs.
  • the methods can be used in vitro, e.g., with a culture of primary or immortalized cells, or in vivo if desired.
  • Figure 1 A is a drawing showing the pTAT expression vector.
  • Figure IB is also a drawing of the pTAT expression vector illustrating a protein "X" fused to 6XHIS (HIS tag) and TAT.
  • Figure 2 shows nucleotide and amino acid sequences of pTAT linker and pTAT
  • a minimal TAT domain is in bold. Underlined sequence designates the minimal TAT domain flanked by glycine residues.
  • FIG. 3 is a drawing outlining a purification and "shock" misfolding protocol. The triangle indicates application of an imidazole concentration ramp. “Desalt” indicates desalting of the shock misfolded fusion protein.
  • Figure 4 is a representation of an SDS-PAGE gel stained with Coomassie Blue.
  • the gel shows various fractions obtained from purification of TAT-pl6 wt using the protocol outlined in Fig. 3.
  • Figure 5 is a representation of an SDS-PAGE gel stained with Coomassie Blue. The gel compares TAT-p 16 wt before (lane 1) and after (lane 2) freeze-thaw of sample stored in 10% glycerol and frozen at -80 C
  • Figures 6A-F are histograms obtained by analyzing FITC-labeled TAT fusion proteins using fluorescence activated cell sorting (FACS).
  • FITC-labeled TAT-p 16 wt (6A) and TAT-HSV TK (6B) fusion proteins were added to Jurkat T cell cultures and analyzed by FACS at 40 and 160 min post addition.
  • FITC-labeled TAT-HSV TK fusion protein was added to human whole blood (6C) or large, nucleated blood cells (6D) were analyzed by FACS at 1 hr post addition.
  • Figures 7 A, B are photomicrographs showing confocal microscopy of Jurkat T cells transduced with control (7 A) or TAT-p 16 wt -FITC protein (7B).
  • Figure 8 A and 8B are representations of an SDS-PAGE gel showing formation of in vivo complexes of TAT-pl6 wt with Cdk6 and TAT-I 35 El A with pRb.
  • pl ⁇ (-l-) Jurkat T cells were transduced with 10 and 200 nM of TAT-pl ⁇ 1 TM 1 fusion proteins during 35 S- methionine labeling of cellular proteins for 4 hr (8 A).
  • Keratinocytes were labeled with 35 S-methionine in the presence of 100 nM TAT-13SElA mut or 100 nM TAT- 13S ElA wt fusion proteins, treated as above and immunoprecipitated with anti-E7 or anti-El A antibodies followed by anti-pRb antibodies and SDS-PAGE resolution (8B).
  • the positions of Cdk6 and pRb are as indicated.
  • the symbol " ⁇ ” followed by a protein designation indicates treatment with an antibody specific for that protein.
  • IP indicates immunopurification using pl6 wt or ⁇ cdk ⁇ antibodies and "mut” denotes pl6 mut protein.
  • Figures 9A-E are graphs illustrating Gl-phase specific arrest of pl6(-) Jurkat T cells by transduction of TAT-p 16 wt protein.
  • Figure 10A is a schematic drawing showing misfolded fusion proteins and native fusion protein adjacent to a Gibbs free energy ( ⁇ G) diagram. The misfolded fusion proteins are energetically unstable relative to the native fusion protein.
  • Figure 1 OB is a model illustrating enhanced transduction of misfolded fusion protein relative to its native protein conformation.
  • the transduced misfolded fusion protein is renatured in the transduced cell by a chaperon Hsp 90.
  • FIGS 11 A-l IF are representations of photomicrographs showing that a misfolded TAT-p27 wt fusion protein is capable of facilitating cell movement.
  • Figure 12 is a graph showing percentage of cell migration following transduction with TAT-p27 wt in soluble and native folded form (SL) versus denatured and misfolded (DN) form.
  • the present invention features highly efficient methods for transducing a fusion molecule into a desired cell or group of cells.
  • the methods generally involve denaturing the fusion molecule and then subjecting the denatured fusion molecule to conditions specified herein.
  • the misfolded fusion molecule is then contacted to cells or groups of cells of interest to transduce the fusion molecule into those cells.
  • the present methods are highly efficient and are capable of substantially enhancing transduction efficiency of a variety of fusion molecules. Further provided are misfolded fusion molecules and methods of making those misfolded fusion molecules.
  • Transduction efficiency can be measured by one or a combination of different strategies.
  • the transduction efficiency as a given fusion protein can be measured by monitoring the rate at which that fusion protein can be measured by monitoring the rate at which that fusion protein enters cells or group of cells.
  • a more preferred method of measuring transduction efficiency is by determining the biological activity of the fusion protein once inside the cell. Biological activity can be measured by a variety of ways provided herein.
  • Preferred misfolded fusion molecules of this invention can transduce at least about 20%, 30%, 40%, 50%, 60%, 70%, 80%, preferably at least about 90%, and more preferably at least about 95%> or even about 100% of the total number of targeted cells as measured by assays specified below.
  • the transduction efficiency of a misfolded fusion molecule of interest can be measured and quantified if desired by a variety of conventional approaches.
  • the approaches involve measuring parameters of transduction with reference to a suitable control molecule.
  • the control molecule will be transduced under the same or nearly the same conditions as the misfolded fusion molecule.
  • the control molecule will be the fusion molecule in its native conformation, i.e., not having been exposed during its isolation to denaturation and "shock" misfolding conditions described herein.
  • the transduction efficiency can be expressed in a variety of ways including the percent increase in the efficiency relative to transduction with a desired control molecule.
  • the fusion molecule has been denatured by exposure to a denaturing agent followed by substantial renaturation.
  • the denatured fusion molecule is typically renatured by dialysis into a physiologically acceptable buffer such as phosphate buffered saline (PBS).
  • PBS phosphate buffered saline
  • Many, but not all, of the intramolecular bonds present in the renatured fusion molecule e.g., hydrogen and ionic bonds
  • Such fusion molecules are also sometimes referred to herein as "denatured dialyzed" fusion molecules.
  • native protein shape and/or structure resulting from contact with an essentially physiological environment, e.g., the cell cytoplasm and/or a physiologically acceptable buffer such as buffered saline.
  • denatured protein shape and/or structure resulting from contact with an essentially chaotropic environment, e.g., exposure to one or more of the denaturing agents described herein.
  • Most protein molecules described herein will retain substantial activity in a native shape but will lose most or all of that activity when denatured, e.g., from about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or greater activity, when compared to the corresponding native molecule.
  • Denaturation can include e.g. unfolding of the native molecule sufficient to transform the native protein into a random loop (coil) configuration. Denaturation can be monitored by a number of recognized methods including measuring protein activity, conducting viscosity measurements, and/or analyzing optical rotation spectra.
  • the term “increased efficiency" or similar term as it relates to transduction of a desired fusion protein is meant at least one of: 1) increasing the percentage of molecules that are in contact with the target cells that are delivered into the cell, 2) increasing the rate of protein transfer into target cells, 3) increasing the percentage of cells exposed to the protein that accumulate the protein, 4) increasing refolding in situ or inside cells, and 5) increasing biological activity of the protein.
  • transduction efficiency can be measured by monitoring the rate of which a desired misfolded fusion molecule enters a cell or, more preferably, measuring biological activity of the protein.
  • the rate determination is typically conducted by standard kinetic analysis using one or more suitable control molecules.
  • a preferred misfolded fusion proteins is capable of transducing target cells faster than the control molecule, generally about 2, 3, 4, 5, 10, up to about 100 times faster than a native control molecule.
  • Particularly preferred misfolded fusion proteins exhibit maximum intracellular concentrations in transduced cells in less then about 1 to 2 hours, more preferably less than an hour, and still more preferably between about 5, 10, 15, 20, 30, 35, up to about 40 to 50 minutes.
  • the analysis is usually conducted by a suitable microscopic or cell sorting technique as described below. In most cases, determining rates of transduction will be useful for fusion molecules having a molecular weight of at least about 50, 60, 70, 80, 90, 100 or more kDa.
  • Additional assays can be conducted that measure levels of the fusion molecule inside transduced cells compared to a suitable control molecule.
  • Specified methods for determining intracellular levels of the fusion molecules in transduced cells generally involve conventional techniques of protein detection in living cells, including but not limited to Western immunoblotting of cell extracts using antibodies to the protein of interest, microscopy, e.g., fluorescence microscopy, or cytometric determinations using fluorescence activated cell sorting (FACS).
  • the control molecule is detectably- labeled to assist in the measurements, e.g., by attaching a detectable tag. Examples of suitably detectable tags include certain amino acid sequences and include those specified fluorescent proteins described below.
  • Particularly preferred misfolded fusion molecules of this invention are capable of increasing the intracellular levels of transduced fusion molecule by about 2, 5, 10, 20, 30, 50, 70, 100, 200 or more fold when compared to a suitable native control molecule.
  • a preferred assay for measuring the transduction efficiency is monitoring the biological activity of the fusion molecule once inside the cell. In many instances, monitoring biological activity will be useful for fusion molecules having a molecular weight of less than about 45, 40, 35, 30, 25, 20 or 15 kDa.
  • misfolded fusion molecules of this invention include misfolded fusion proteins.
  • fusion proteins include those exhibiting a specified biological activity particularly when transduced into a target cell or group of such cells. That activity can be measured and quantified if desired to determine transduction efficiency for a particular misfolded fusion protein relative to a suitable control molecule.
  • Examples of such assays include those which measure cell replication, cell adhesion, oncogenic transformation, cell blebbing, cell kinesis, cell division, cell death (apoptotic and necrotic), fertilization, expression of a specified cell protein such as a receptor, transcription, immunological reactivity, protein synthesis, including translation, protein modification, and secretion; protein degradation, glycosylation, and phagocytosis.
  • a specified cell protein such as a receptor
  • transcription immunological reactivity
  • protein synthesis including translation, protein modification, and secretion
  • protein degradation glycosylation, and phagocytosis
  • fusion molecule a transduction protein covalently linked (i.e. fused) to a desired molecule by recombinant or chemical methods. If desired, the molecule can be fused to the transducing protein through a peptide linker sequence which can include one or more cleavage sites for an enzyme such as a protease. Specified transducing proteins are discussed more fully below.
  • the molecule of interest can be any one of a protein such as an enzyme, polypeptide, peptide, amino acid, nucleic acid (RNA or DNA), lipid, glycolipid, proteolipid, carbohydrate such as a sugar, glycan, saccharide or polysaccharide, glycoprotein, proteoglycan, a drug or other synthetic or semi-synthetic small molecule, or a hybrid thereof (e.g., an RNA-DNA hybrid molecule).
  • the molecule can be dextrorotatory (D) or levrorotatory (L) as desired.
  • the fusion molecule can include 1, 2, 3, 5, 8, 10, 20, 50 up to about 100 or more of such molecules as desired fused to the transducing protein (or the linker if desired). As noted, that fusion molecule is preferably misfolded in accord with this invention.
  • the peptide linker sequence preferably may comprise up to about 20 or 30 amino acids, more preferably up to about 10 or 15 amino acids, and still more preferably from about 1 to 5 amino acids.
  • the linker sequence is generally flexible so as not to hold the fusion molecule in a single rigid conformation.
  • the linker sequence can be used, e.g., to space components of the fusion molecule from each other as desired.
  • the peptide linker sequence can be positioned between the protein transduction domain and the protein sequence, e.g., to chemically cross-link same and to provide molecular flexibility.
  • each component of the fusion protein can be spaced from another component by one or more suitable peptide linker sequences, e.g., to provide specified enzyme recognition sites, particularly protease cleavage sites; or tags, provided that the peptide linker sequences do not significantly impact the function for which the fusion protein is intended.
  • suitable peptide linker sequences e.g., to provide specified enzyme recognition sites, particularly protease cleavage sites; or tags, provided that the peptide linker sequences do not significantly impact the function for which the fusion protein is intended.
  • the molecular weight of the molecule will vary depending on intended use but will generally be between about 0.1 to 100 kD or greater up to about 500 to 1000 kD. Preferably, the molecular weight of the molecule will be between about 0.1, 0.2, 0.5, 1, 2, 5, 10, 20, 30, or 50 kD up to about 100 kD as determined by SDS-PAGE gel electrophoresis, sedimentation centrifugation or other suitable means.
  • the molecular weight of the fusion molecule will vary in accord with intended use but will generally be about 5, 10, 20, 30, 40, 50, 100, 200, 500, or 1000 kDa or more as measured by centrifugation sedimentation or SDS-PAGE gel electrophoresis.
  • fusion molecules in accord with the present invention are fusion proteins comprising the transducing protein (sometimes referred to as a transduction domain) fused to a desired protein.
  • the protein fused to the transduction domain can be, e.g., a zymogen, an enzyme, a binding partner for another amino acid or nucleic acid sequence, an immunological molecule such as an antigen binding antibody fragment, or a structural protein.
  • Additional fusion proteins suitable for use in accord with this invention have been described in U.S. Provisional Application No. 60/069012, entitled “Anti-Pathogen System and Methods Of Use” filed on December 10, 1997, now filed as PCT/US98/26358 and U.S. application serial no. 09/208966, and also described in U.S.
  • Preferred misfolded fusion molecules of this invention are capable of enhancing transduction of specified cells or groups of cells including tissues and organs by about 2, 5, 10, 20, 50, 100, or about 200 fold or more when compared to transduction with a suitable control molecule, preferably a native fusion molecule corresponding to the misfolded fusion molecule of interest. Preferred methods for measuring enhancement of protein transduction are described in more detail below.
  • misfolded is used herein to denote a misfolded fusion molecule that has been denatured and then subjected to one or more specified conditions as disclosed herein. Without wishing to be bound to any particular theory, it is believed that when the denatured fusion molecule is exposed to the conditions it becomes energetically unstable relative to its native or near-native conformation. It is believed that the energetic instability contributes significantly to the enhanced transduction capacity of the fusion molecules. In many instances, the misfolded fusion molecules will exhibit a Gibbs free energy ( ⁇ G) that is about 2, 3, 5, 10, 20, 50, or 100 up to about 250 fold or more higher than the ⁇ G of the native molecule.
  • ⁇ G Gibbs free energy
  • the Gibbs free energy of a desired molecule can be determined by a variety of conventional thermodynamic approaches.
  • Reference herein to a misfolded fusion molecule having a "high ⁇ G” means that at least in theory the molecule has a large negative Gibbs free energy and that folding of the misfold molecule can proceed spontaneously under appropriate conditions.
  • reference to a "low ⁇ G” means that the fusion molecule has at least in theory a zero or positive Gibbs free energy compared to its native conformation indicative of an essentially stable fusion molecule that will not fold (or unfold) spontaneously. See generally Edsall, J.T. and Gutfreund, H., Biothermodynamics: The Study of Biochemical Processes at Equilibrium, (Wiley, 1983).
  • misfolded fusion proteins are readily distinguishable.
  • misfolded fusion proteins are capable of significantly enhancing transduction and exhibit a theoretically higher Gibbs free energy than the same proteins in a native form.
  • misfolded fusion molecules can be distinguished from native or denatured proteins in a variety of ways, e.g., by viscosity and/or optical rotation spectra. See e.g., Edsall and J.T and Gutfreund, H, supra.
  • Misfolded fusion proteins of the invention can be further identified by analysis of biochemical and/or biological activity of the misfolded protein relative to the same protein in native form.
  • a misfolded protein of the invention will exhibit decreased biological and/or biochemical activity, e.g. about 20%>, 30%, 40%, 50%), 60%), 10%, 80%) or more of a decrease of biological and/or biochemical activity relative to the same protein in native form.
  • a misfolded protein of the invention will exhibit a complete or essentially complete loss of biological and/or biochemical activity relative to the same protein in native form.
  • Such analysis of decreased biochemical and/or biological activity of a misfolded fusion protein of the invention relative to the same protein in native form can be readily determined by standard assays for the particular biological or biochemical property.
  • a denaturing agent suitable for use in accord with this invention is any agent including a chaotropic agent which is capable of substantially disrupting intramolecular bonds (e.g., hydrogen, ionic or covalent) in a protein, polypeptide or peptide.
  • Illustrative denaturing agents include certain organic compounds, salts, temperature (e.g., heat), " and sound (e.g., sonication).
  • the organic compounds can include urea, particularly in a concentration of between about 4 to 8M, preferably about 8M urea, guanidinium-HCl, and certain mercaptans such as ⁇ -mercaptoethanol.
  • the denaturing agent may be a detergent such as an ionic detergent, e.g., sodium dodecyl sulfate, (SDS); as well as other detergents such as Brijj, Nonidet-P40, and Triton-X-100.
  • an ionic detergent e.g., sodium dodecyl sulfate, (SDS)
  • other detergents such as Brijj, Nonidet-P40, and Triton-X-100.
  • Further contemplated denaturing agents include high concentrations of a salt (e.g., molar amounts) such as NaCl, KC1, and the like.
  • a solution suitable for forming the misfolded fusion molecules of this invention is one which supports formation of a misfolded fusion molecule.
  • the solution will be an aqueous buffer (or more than one of such a buffer) such as those generally known in the field. Particular examples of such buffers are described below and in Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York (1989), Sambrook et al., Molecular Cloning: A Laboratory Manual. (2nd ed. (1989), and Harlow and Lane Antibodies: A Laboratory Manual, CSH Publications, N.Y. (1988).
  • suitable aqueous solutions referenced herein typically have a buffering compound to establish pH (e.g., Tris or Hepes), typically within a pH range of about 5-9, and an ionic strength range between about 2mM and 500mM. Sometimes a protease inhibitor or mild non-ionic detergent is added. Additionally, a carrier protein may be added if desired such as bovine serum albumin (BSA) to a few mg/ml.
  • BSA bovine serum albumin
  • Further illustrative aqueous buffers include standard phosphate buffered saline, tris-buffered saline, Hepes-buffered or other well known buffers and cell media formulations.
  • a misfolded fusion molecule of the present invention can be made by one or a combination of strategies.
  • a preferred method of misfolding a fusion molecule is by one or more of the following steps a) to c) as follows: a) contacting a native (or near-native) fusion molecule with one or more denaturing agents under conditions which denature the fusion molecule, b) applying the denatured fusion molecule to a first chromatographic implementation (e.g., an affinity column) sufficient to bind the denatured fusion molecule to the implementation in the presence of the denaturing agents, c) eluting the denatured fusion molecule from the first chromatographic implementation under conditions which concentrate the denatured fusion molecule, and then carrying out at least one of the following three methods (i.e. method 1) or method 2a)-2d) or method 3))
  • the aqueous buffer is preferably sufficient to decrease or eliminate presence of the denaturing agents and to form the misfolded fusion molecule, 2c) eluting the misfolded fusion protein from the second column by contacting the fusion molecule with a second eluting solution comprising a salt gradient sufficient to release the fusion molecule from the second column; and optionally
  • a third chromatographic implementation e.g., a desalting column
  • the misfolded fusion molecule is purified as described and is provided as a substantially pure preparation (preferably sterile) suitable for pharmaceutical or research use.
  • a substantially pure preparation preferably sterile
  • Further preferred in the method are specified denaturing agents, eluting solutions, and gradient conditions disclosed in the examples which follow.
  • misfolded fusion molecules made by the one or more of the above steps a) to c) are misfolded fusion proteins.
  • the misfolded fusion proteins can be made in accord with the method by introducing a nucleic acid encoding the fusion protein into host cells in suitable media under conditions sufficient to express the fusion protein in the cells as an insoluble and/or soluble fraction.
  • the insoluble fraction can include inclusion bodies.
  • the nucleic acid can be introduced into the host cells by any acceptable method, e.g., transformation, biolistic transfer, or infection using a suitable recombinant vector. Examples of such vectors are described below. See Example 1.
  • the fusion protein is isolated from the cell fraction by contact with one or more denaturing agents such as urea or guanadine sufficient to denature the fusion protein.
  • the denatured fusion protein is then subjected to one or more of steps b) through g) above sufficient to form the misfolded fusion protein.
  • the misfolded fusion protein is provided as a sterile and substantially pure preparation suitable for pharmaceutical or cell-culture use.
  • a variety of conventional chromatographic implementations are suitable for use in accord with this invention including but not limited to affinity, immunoaffinity, ion exchange, sizing, and desalting columns.
  • Another preferred method for producing a misfolded fusion protein includes one or more of the following steps: a) introducing a nucleic acid encoding a fusion protein into host cells in media under conditions sufficient to express the fusion protein in the host cells, b) preparing a fraction from the host cells, c) isolating the fusion protein from the fraction in the presence of one or more denaturing agents sufficient to denature and solublize the fusion protein, d) contacting the denatured fusion protein with a solution, preferably an aqueous solution; and e) forming the misfolded fusion protein in the solution from the denatured fusion protein.
  • the cell fraction can be insoluble, soluble, or it can include insoluble and soluble cell constituents.
  • misfolding of a fusion molecule can be analyzed and further confirmed if desired by a variety of conventional techniques including e.g. performing circular dichroism, kinetic folding analysis, optical spectroscopy, NMR spectroscopy (including solution NMR) and X-ray crystallography. Standard calorimetric measurements can also be performed if desired.
  • Other known methods for making structural determination of proteins also can be employed as will be appreciated to those skilled in the art upon consideration of the present disclosure. See, for example, methods disclosed in C. Tanford, Physical Chemistry of Macromolecules and other references cited herein.
  • preferred misfolded fusion molecules of the present invention are fully soluble in aqueous solution.
  • the fusion molecule and particularly a fusion protein that is not readily sedimented under low G-force centrifugation (e.g. less than about 30,000 revolutions per minute in a standard centrifuge) from an aqueous buffer, e.g., cell media.
  • the fusion molecule is soluble if the it remains in aqueous solution at a temperature greater than about 5-37°C and at or near neutral pH in the presence of low or no concentration of an anionic or non-ionic detergent. Under these conditions, a soluble protein will often have a low sedimentation value e.g., less than about 10 to 50 svedberg units.
  • polypeptide refers to any polymer preferably consisting essentially of any of the 20 natural amino acids regardless of its size.
  • protein is often used in reference to relatively large proteins, and “peptide” is often used in reference to small polypeptides, use of these terms in the field often overlaps.
  • polypeptide refers generally to proteins, polypeptides, and peptides unless otherwise noted.
  • the term "cell” is intended to include any primary or immortalized cell line, any group of such cells, such as a tissue or an organ that is capable of being transduced.
  • the cell is of mammalian and particularly of human origin although in some cases, the cell can be derived from sheep, cow or horse.
  • Particularly preferred are primate and more particularly human cells, tissue or organs. Examples of such cells include peripheral blood lymphocytes, whole blood cells, bone marrow stem cells, diploid fibroblasts, fibrosarcoma cells, keratinocytes, leukemic T- cells, osteocarcinomas, gliomas, murine 3T3 cells, hepatocarcinomas, and macrophages.
  • cell is intended to mean a cell, e.g., E.coli used to express a desired fusion protein. Also meant are those cells which serve as “targets” for transducing molecules of this invention.
  • Suitable cells can be obtained from a variety of public and commercial sources such as the American Type Culture Collection (ATCC) 12301 Parklawn Drive, Rockville, MD 20852.
  • ATCC American Type Culture Collection
  • a "host cell” in accord with the invention can also be a cell such as a bacterial cell (e.g., E. coli) that can be used to express a desired fusion protein.
  • a bacterial cell e.g., E. coli
  • Other suitable bacterial host cells are known in the field.
  • the present invention pertains to fusion molecules and particularly to misfolded fusion proteins.
  • the term fusion protein as specified above is intended to describe at least two polypeptides, typically from different sources, which are operatively linked. With regard to the polypeptides, the term "operatively linked" is intended to mean that the two polypeptides are connected in manner such that each polypeptide can serve its intended function. Typically, the two polypeptides are covalently attached through peptide bonds and can be separated by a peptide linker if desired.
  • the fusion protein is preferably produced by standard recombinant DNA techniques. For example, a DNA molecule encoding the transduction domain is ligated to another DNA molecule encoding the protein or polypeptide, and the resultant hybrid DNA molecule is expressed in a host cell to produce the fusion protein.
  • the DNA molecules are ligated to each other in a 5' to 3' orientation such that, after ligation, the translational frame of the encoded polypeptides is not altered (i.e., the DNA molecules are ligated to each other in-frame).
  • the resulting DNA molecules encode an in-frame fusion protein.
  • fusion molecules comprising multiple components, for example more than one transducing domain or more than one covalently linked molecule are within the scope of this invention.
  • the transduction domain of the fusion molecule can be nearly any synthetic or naturally occurring amino acid sequence that can transduce or assist in the transduction of the fusion molecule in its misfolded form.
  • transduction can be achieved in accord with the invention by use of an HIV TAT protein or fragment thereof that is covalently linked to the fusion molecule.
  • the transducing protein can be the Antennapedia homeodomain or the HSV VP22 sequence, or suitable transducing fragments thereof known in the field.
  • transduction domains comprising or consisting of synthetic peptides including TAT or ANTP derivatives.
  • the fusion molecule is suitably misfolded to enhance transduction into the target cells. See e.g., Frankel, A.D. and Pabo, CO., supra; Falwell, S., et al. supra; Chen, et al. supra; U.S. Pat. Nos. 5,652,122 and PCT WO/04686.
  • transducing protein will be guided by several parameters including the extent of transduction desired.
  • a suitable transducing protein preferably will be capable of transducing at least about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%), 95%o or even up to about 100% of the target cells when misfolded in accord with this invention.
  • the efficiency of transduction of a particular transducing domain can be measured by one or a combination of means including measuring the percentage of transduced cells versus non-transduced cells.
  • Particular preferred transduction domains are capable of transducing up to about 100% of the total number of targeted cells.
  • the efficiency of transduction of a misfolded fusion molecule will be determined by specific reference to a native or near-native form of that fusion molecule to generate activity.
  • the determinations of transduction efficiency with respect to a misfolded fusion molecule of interest can be performed on cells or groups of such cells including tissue and organs as needed. Illustrative transduction efficiency assays are described in more detail below.
  • the entry and exit rates can be readily determined or at least approximated by standard kinetic analysis using detectably-labeled fusion molecules. Typically, the ratio of the entry rate to the exit rate will be in the range of about 5 to 100 up to about 1000.
  • the fusion molecules of this invention can be made chemically cross-linking techniques such as those disclosed in Means, G.E. and Feeney, R.E. (1974) in Chemical Modification of Proteins, Holden-Day. See also, S.S. Wong (1991) in Chemistry of Protein Conjugation and Cross-Linking, CRC Press.
  • the fusion proteins are made by standard recombinant manipulations to make a suitable genetic in-frame fusion. See generally Ausubel et al. supra and Sambrook et al. supra
  • the misfolded fusion molecules of the present invention be substantially pure. That is, the fusion molecules and particularly fusion proteins have been isolated from cell substituents that can accompany it. Typically, the fusion molecules are present in at least 90 to 95% homogeneity (w/w). Misfolded fusion molecules and particularly misfolded fusion proteins having at least 98 to 99% homogeneity (w/w) are most preferred for many pharmaceutical, clinical and research applications.
  • the fusion molecule should be substantially free of contaminants for therapeutic applications.
  • the soluble fusion molecules can be used therapeutically, or in performing in vitro or in vivo assays as disclosed herein. Substantial purity can be determined by a variety of standard techniques such as chromatography and gel electrophoresis.
  • fusion proteins of the present invention can be separated and purified by appropriate combination of known techniques. These methods include, for example, methods utilizing solubility such as salt precipitation and solvent precipitation, methods utilizing the difference in molecular weight such as dialysis, ultra-filtration, gel-filtration, and SDS-polyacrylamide gel electrophoresis, methods utilizing a difference in electrical charge such as ion-exchange column chromatography, methods utilizing specific affinity such as affinity chromatograph, methods utilizing a difference in hydrophobicity such as reverse-phase high performance liquid chromatograph and methods utilizing a difference in isoelectric point, such as isoelectric focusing electrophoresis, metal affinity columns such as Ni-NTA. See generally Sambrook et al. and Ausubel et al. supra for disclosure relating to these methods.
  • the fusion proteins are typically misfolded as described herein.
  • the present invention substantially enhances transduction efficiency of a variety of fusion molecules.
  • about 300 ⁇ M of a 20 amino acid pl6 peptidyl mimetic can be fused to the TAT transduction domain to obtain a Gi phase cell cycle arrest.
  • the present invention only requires use of 300 nM of full length TAT-p 16 protein to achieve the same effect.
  • the pi 6 peptidyl mimetic induces an apoptotic side-effect, whereas the full-length protein does not.
  • transduction of full length pl6 protein (156 amino acids) into cells increases the specificity of the biological response by three orders of magnitude compared to a peptidyl mimetic.
  • a desired TAT fusion protein was isolated under denaturing conditions sufficient to produce what is believed to be a highly energetic misfolded protein. More particularly, misfolding of the TAT fusion protein was optimized by providing "shock" misfolding conditions. That is, the TAT- fusion protein was subjected to aqueous conditions following denaturation.
  • Figure 3 provides an outline of the "shock" misfolding process specifically described below.
  • the "shock" misfolding purification protocol detailed below achieved at least two goals.
  • transduced proteins become refolded by proteins such as chaperones which have been shown to refold misfolded proteins into their active state.
  • a suitable chaperone can be Hsp90.
  • FIGS 10a and 10b are schematic representations which illustrate the enhanced transduction efficiency provided by the present invention.
  • cDNA sequences referenced herein can be obtained from a variety of public and commercial sources.
  • one source is the National Center for Biotechnology Information
  • Genbank Genetic Sequence Data Bank
  • Genbank provides a variety of cDNA sequences suitable for use with the present invention. Selection of a suitable cDNA from Genbank or another appropriate source of cDNAs will be guided, e.g., by the type of fusion molecule desired to be transduced (i.e. enzyme, zymogen, nucleic acid, etc.).
  • Table A illustrates preferred methods of making shock misfolded fusion molecules as described more fully in the examples which follow.
  • the table also points out the energetics and relative transduction efficiency of each preferred method.
  • the terms “poor”, “good” and “best” will be understood to be relative terms that are meant to compare the methods in the table to recognized prior methods of transducing fusion proteins.
  • FIG. lb shows the pTAT vector encoded a fusion protein comprising HIS, TAT and A protein "X" which can be any of the proteins described herein.
  • Figure 2 shows a nucleotide sequence (SEQ ID NO:l 1) and amino acid sequence (SEQ ID NO: 12) of the pTAT linker as well as a nucleotide sequence (SEQ ID NO:6) and amino acid sequence (SEQ ID NO: 13) of the pTAT-HA linker.
  • pTAT and pTAT-HA (tag) bacterial expression vectors were generated by inserting an oligonucleotide corresponding to the 11 amino acid TAT domain flanked by glycine residues to allow for free-bound rotation of the TAT domain (G- YGRKKRRQRRR-G) (SEQ ID NO: 14) into the BamHI site of pREST-A (Invitrogen).
  • a polylinker was added C terminal to the TAT domain (see Figure 1 A and IB) by inserting a second oligonucleotide into the Ncol site (5' or N') and Eco RI site that contained NcoI-Kpnl-Agel-XhoI-Sphl-EcoRI cloning sites. This LCS is followed by the remaining original polylinker of the pREST-A plasmid that includes BstBI-Hind III sites.
  • the pTAT-HA plasmid was made by inserting an oligonucleotide encoding the HA tag (YPYDVPDYA SEQ ID NO: 15; see Figure 2 where sequence is bold) flanked by glycines into the Ncol site of pTAT.
  • the 5' or N' Ncol site was inactivated leaving only the 3' or C to the HA tag followed by the above polylinker.
  • the HA tag allows the detection of the fusion protein by immunoblot, immunoprecipitation or immunohistostaining by using 12CA5 anti-HA antibodies.
  • the nucleotide and amino acid sequences of each linker are set forth in Figure 2.
  • the pRSET-A backbone encodes ampicillin resistance, fl, ori, ColEl ori (plasmid replication) and the transcript is driven by a T7 RNA polymerase promoter.
  • the pTAT vector contains an N' terminal 6-histidine leader followed by a minimal, highly basic 11 amino acid TAT protein transduction domain, that is flanked by glycine residues for free bond rotation, followed by a polylinker (Fig. la).
  • HSV-TK HSV-TK cDNA. See e.g., Hall, M. and Peters, G. (1996) Advances in Cancer Res. 68: 67.
  • the pTAT vector served as a parental vector for making the fusion proteins.
  • a cDNA encoding a desired amino acid sequence was ligated into the pTAT vector polylinker sometimes referred to as a multiple cloning SITE or "MCS" by standard means to produce an in- frame fusion protein.
  • MCS multiple cloning SITE
  • DH5- ⁇ bacteria were used as host cells to propagate vectors encoding the in- frame fusion proteins.
  • BL21(DE3) pLysS cells Novagen
  • the pTAT fusion proteins were subsequently analyzed by SDS-PAGE gel electrophoresis.
  • the production of specific TAT in-frame fusion proteins are desirable as follows:
  • TAT-p 16 fusion proteins pTAT-pl6 wild type (sometimes referred to as pl6 wt ) and pTAT-pl6 mutant vectors were generated by ligation of an appropriate cDNA into the pTAT vector polylinker.
  • the mutant pl6 protein is sometimes referred to as pl6 mut or pl6 INK4a to designate the R87P mutation in the wild-type pi 6 sequence. See Hall et al., supra. Advances in Cancer Res. 68, 67-108 (1996).
  • the cDNAs were individually inserted into the NcoI/EcoRI site of the pTAT vector polylinker.
  • the cDNA sequence for the pi 6 protein can be obtained from Genbank.
  • the molecular weight of the fusion proteins encoded by the vectors was about 20 kDa as estimated by SDS-page gel electrophoresis.
  • TAT-HPV E7 fusion protein (Strain HPV16): pTAT-HPV E7 wt and pTAT-HPV E7 mutant vectors were made by individually inserting cDNAs encoding the E7 wt or E7 mutant proteins into the pTAT vector polylinker (NcoI/EcoRI).
  • the cDNA sequence for E7 wt can be obtained from Genbank.
  • the mutant E7 protein is sometimes referred to as E7 mu to denote the deletion in the E7 wt sequence of the wild-type E7 sequence.
  • the molecular weight of the fusion proteins encoded by the vectors was about 18 kD as estimated by SDS-page gel electrophoresis.
  • TAT- 13 S E 1 A fusion protein (Adeno virus strain 5 ) :
  • a pTAT-13S El A vector were made by inserting a cDNA encoding the 13S El A protein into the pTAT vector polylinker (NcoI/EcoRI site).
  • the cDNA sequence encoding the 13S El A protein can be obtained from Genbank.
  • the molecular weight of the fusion protein encoded by the vector was about 61 kD as estimated by SDS-page gel electrophoresis.
  • TAT-p27 K l fusion protein A pTAT- p27 K ⁇ pl vector was made by inserting a cDNA encoding the p27 K l protein into the pTAT vector polylinker (Nco I/EcoRI).
  • the DNA sequence of the p27 K ⁇ pl protein can be obtained from Genbank.
  • the molecular weight of the fusion protein encoded by the vector was about 30 kD as estimated by SDS-gel electrophoresis.
  • a pTAT- Rb vector was made by inserting a cDNA encoding the Retinoblastoma (Rb) protein into the pTAT vector polylinker (Nco/EcoRl site).
  • the cDNA sequence encoding the RB protein can be obtained from Genbank.
  • the molecular weight of the fusion protein encoded by the vector was about 115 kD as estimated by SDS-PAGE gel electrophoresis.
  • a TAT-HSV TK vector was made by the following method described in the Provisional U.S. Application No. 60/069012.
  • the HSV-1 TK sequence was obtained from Genbank (Accession No. J02224).
  • PCR primers were generated that corresponded to the N* and C end of TK. After PCR, the DNA fragment was cut with NcoI/EcoRI and inserted into the corresponding polylinker site of the pTAT vector. The following primers were used in the method:
  • TK reverse PCR primer 39MER: 5' GGC GGG CCG GGA ATT CTC AGT TAG CCT CCC CCA TCT CCC 3' (SEQ ID NO: 17)
  • the molecular weight of the TAT-TK fusion protein encoded by the vector was about 40 kDa as estimated by SDS-PAGE gel electrophoresis.
  • the TAT-CDK2 fusion protein was made along the lines of the fusion proteins described above.
  • the CDK2 cDNA sequence can be obtained from Genbank.
  • TAT fusion proteins preparation and use of other fusion proteins has been described in the U.S. provisional application No. 60/069012 filed on December 10, 1997.
  • the U.S. provisional application discloses production of fusion proteins comprising TAT and a potentially toxic zymogen, proenzyme or preproenzyme domain.
  • these fusion proteins can be misfolded in accord with the present invention to enhance transduction in desired cells or groups of cells.
  • Example 3 Preparation of Misfolded TAT Fusion Proteins
  • the protocol is sometimes referred to herein as a "misfolding” or “shock misfolding” protocol or similar phrase.
  • a fusion protein made in accordance with the misfolding protocol is sometimes referred to herein as "shock" misfolded fusion protein or like term.
  • TAT fusion proteins were purified by sonication (3 bursts, 15 seconds each) of transfected BL21(DE3) pLysS cells (Novagen) obtained from a 5 hr 1 L culture. That culture was inoculated with 100 ml from an overnight culture in 10 ml of buffer A (8M urea / 20 mM HEPES (pH 7.2 (100 mM NaCl)). Cell lysates were resolved by centrifugation, loaded onto an Ni-NTA column (Qiagen) in buffer A plus 20mM imidazole. The column was then washed in 10X column volume, eluted by increasing imidazole concentration in buffer A (stepwise).
  • Preparation of the misfolded fusion molecule can proceed by, but not limited to, 1) dialysis, 2) desalting over a Mono Q/S column, or 3) rapid desalting.
  • 1-3 ml of the denatured fusion protein was placed in a dialysis cassette (Pierce). The cassette was then placed in 4 liters of PBS at 4°C and allowed to dialyze. The PBS was changed 3 times every 4 hours for a period of about 12 to 24 hours to achieve salt reduction and misfolding.
  • the misfolded protein was stored in 20 mM HEPES (pH 7.2)/137 mM NaCl and frozen in 10% glycerol at -80°C.
  • TAT fusion proteins remain highly concentrated and resistant to freeze-thaw denaturation when stored in 10% glycerol at -80°C (Fig. 5, lanes 1 or 2).
  • TAT fusion protein fractions from the misfolding protocol were analyzed by conventional SDS-polyacrylamide gel electrophoresis (Fig. 4, lanes 1-10). TAT fusion proteins were found to comprise approximately 1-10% of the total bacterial cellular lysate; however, >99%> is insoluble and present in inclusion bodies (see Fig. 4, lane 1).
  • bacterial pellets were sonicated in 8 M urea and the lysate applied to the Ni-NTA column (see Fig. 3).
  • Column fractions comprising recombinant TAT fusion proteins were eluted by increasing the imidazole concentration in 8 M urea (Fig. 4, lines 7-10). Flow through and wash fractions from the Ni-NTA column were also analyzed (Fig. 4, lines 3 and 5).
  • FITC-labeled (fluorescent) TAT fusion proteins were generated by fluorescent labeling (Pierce) of misfolded protein according to standard methods. Labeled proteins were purified by gel purification in PBS on an S-12 column attached to an FPLC (Pharmacia). The misfolded and FITC-labeled fusion proteins were typically added directly to culture media.
  • Example 4 TAT-Fusion Protein Transduction into Cultured and Primary Cells
  • TAT fusion proteins produced in Example 2 above were analyzed to determine ability to efficiently transduce into cultured or primary cells. In general, it was found that all TAT fusion proteins transduced efficiently into the cells.
  • FITC-conjugated TAT-pl6 wt or TAT-HSV-TK fusion protein was added to the culture media of Jurkat T cells and/or human whole blood cells. After about 15, 30 or 45 minutes, labeled protein was followed by flow cytometry analysis (FACS) (Figs. 6A-E; 7A, 7B). The results show rapid transduction of both fusion proteins into >99% of target cells, achieving maximum intracellular concentrations in less than 40 min (Figs. 6 A, B). It was noted that a narrow intracellular concentration range existed within the population as measured by the FACS peak width between control and transduced cells. Similar results were observed with TAT-p 16 mut FITC protein.
  • TAT fusion proteins were capable of transducing into primary cells.
  • whole blood cells were treated with fluorescein conjugated TAT-HSV-TK protein and analyzed by FACS at 1 hr post-addition (Figs. 6C, D).
  • TAT-HSV TK-FITC protein uniformly transduced into all cells present in whole human blood, including both nucleated and enucleated cells.
  • each of TAT- pl6 wt , TAT-p 16 mut and TAT-HSV TK proteins were also shown to efficiently transduce into diploid fibroblasts, fibrosarcoma cells, keratinocytes, bone marrow stem cells, peripheral blood lymphocytes (PBLs), leukemic T cells, hepatocellular carcinoma cells, osteosarcoma and NIH 3T3 cells.
  • a concentration-dependent transduction and narrow intracellular concentration was noted as measured by nearly equivocal FACS peak widths between control and transduced cells. About 10,000 cells were analyzed for each histogram. The following TAT fusion proteins were found to transduce efficiently into all tested cells after misfolding: TAT-HPV E7 WT/MUT. protein, TAT-p27 i p pl protein, TAT
  • T protein, and TAT-pRB protein The results show that it is possible to transduce fusion proteins from about 18 to 110 kD into all cells of the population.
  • Table 1 shows biochemical and biological responses induced by transduction of misfolded TAT fusion proteins misfolded in accord with the invention.
  • TAT-13S E1A Bind pRB ND a TAT-CDK2 Dom.-Neg. ND Gi arrest TAT-HSV TK plus Acyclovir ND Cell Killing TAT-HIV Protease In-vivo substrate cleavage ND a. ND not determined.
  • Cell cycle position was determined by staining EtOH fixed cells in propidium iodide and analyzed by flow cytometry (FACS; Becton Dickinson). Uptake of FITC-labeled TAT-p 16, -HSV TK, -El A proteins in Jurkats and/or whole blood cells, was determined by FACS analysis of 10,000 live cells. Confocal microscopy was performed on paraformaldehyde fixed Jurkats transduced with TAT-p 16-FITC and TAT- HSV TK-FITC conjugated proteins.
  • TAT-p 16 and TAT-HSV TK proteins were added to Jurkat T cells at final concentrations of 4 nM, 16 nM, 40 nM and 0.25, 1.25, 10 nM, respectively, and analyzed post-equilibrium (1 hr post-addition) by FACS (Figs. 6E and 6F). Both TAT- p 16-FITC and TAT- HSV TK-FITC proteins showed a concentration dependence for transduction, demonstrating the ability to modulate the intracellular concentration of transduced proteins. In addition, washing and replating of cells pre-loaded with TAT fusion proteins results in the transduction out of the cell in a concentration-dependent manner.
  • Figs. 7A and 7B show confocal microscopy analysis of transduced TAT-p 16- FITC fusion protein. The results demonstrate presence of the fusion protein in the nucleus and cytoplasm of the cell and not merely attached to the cellular membrane. Intracellular fluorescence of TAT-p I6 wt -F1TC protein and the absence of pericellular membrane ring staining was observed (see Figs. 7A-B).
  • Jurkat T cells were labeled in the presence of TAT-pl6 proteins for 4 hr with 250
  • lysates of transduced cells were immunoprecipitated with anti-pl6 antibodies, re-immunoprecipitated with anti-Cdk6 antibodies and then separated by SDS-PAGE gel electrophoresis.
  • TAT-p 16:Cdk6 complexes were immunoprecipitated from whole cell lysates with anti-pl6 antibodies followed by re- immunoprecipitation with anti-Cdk6 antibodies and resolution on SDS-PAGE (Fig. 8A).
  • Transduced TAT-HPV E7 fusion protein pl6 Jurakat T cells were • ee llaabbeelleedd wwiitthh 35 SS--mmeetthhiioonine for 4 to 6 hours and transduced with TAT-13SE1A mut protein or TAT- 13S El A wt protein Immunoprecipitation of the transduced and labeled cells showed the ability of TAT-13S El A protein, but not TAT-E7 mutant protein, to associate with the retinoblastoma tumor suppressor protein (pRb) in vivo (Fig. 8B). These observations indicated that transduced (misfolded)proteins are correctly refolded by chaperones once inside the cell and then are capable of associating with cognate target proteins in vivo.
  • pRb retinoblastoma tumor suppressor protein
  • Figs. 9A-E Jurkat T cells transduced with TAT-pl6 WT protein remained arrested in the Gi phase of the cell cycle in a concentration-dependent fashion, while cells treated with TAT-p 16 protein or untreated control cells progressed from Gi into S/G 2 /M phases.
  • pl6(+) human HaCaT keratinocytes are also arrested by TAT-pl6 WT protein. See Ezhevsky, S.A., (1997). Proc. Natl. Acad. Sci. USA 94, 10699.
  • Example 9 Increased Transduction Efficiency of Shock Misfolded Proteins
  • the transduction efficiency of a desired fusion protein can be determined at ' various steps in the misfolding protocol. See Example 3 and Fig. 3. For example, it is possible to estimate the transduction efficiency after solubilization of the fusion protein from host bacteria, after denaturation and renaturation of the fusion protein, or after denaturation of the fusion protein followed by ion exchange chromatography. Estimation of transduction efficiency is accomplished, e.g., by measuring one or more of transduction rate, intracellular amounts of the fusion protein or amounts or activity of transduced proteins compared with a suitable control.
  • TAT-p27 was measured by ability to induce cell cycle arrest and ability to induce cell scattering in HepG2 cells after 24 to 48 hours. The cell scattering was measured by microscopy. In this experiment it was found that the denatured and shock misfolded TAT-p27 fusion protein transduced the cells greater than 20 fold more efficiently than a denatured and dialyzed TAT-p27 fusion protein.
  • BL21(DE3) pLysS cells (Novagen) were transformed with the TAT-p27 vector described above and propagated for 5 hours in a 1 L culture. That culture was inoculated with 100 ml from an overnight culture. That culture was split into two fractions one of which was denatured and dialyzed as described above and one which was shock misfolded. To shock misfold the fusion protein, an aliquot was mixed and sonicated in about 10 ml of buffer A (8M urea / 20 mM HEPES (pH 7.2 (100 mM NaCl)) to form a "denatured" fraction.
  • buffer A 8M urea / 20 mM HEPES (pH 7.2 (100 mM NaCl)
  • That denatured fraction was clarified and then loaded onto an Ni-NTA column (Quiagen) in buffer A plus 20 mM imidazole. The column was then washed in 10X column volume, eluted by increasing imidazole concentration in buffer A (stepwise) and then applied to a Mono-Q column on an FPLC (Pharmacia) in 4M urea / 20 mM HEPES (pH 7.2, (50 mM NaCl)). The resulting "denatured and shock” misfolded TAT-p27 fusion protein was eluted, desalted and stored as described in Example 2. It was found that the denatured and shock misfolded p27 fusion protein was " greater than 20 fold more efficient in transducing cells and in inducing cell scattering then the denatured and dialyzed fusion protein.
  • shock misfolding protocol can produce misfolded TAT fusion proteins that have a greater than 2, 5, 10, 20, 50, 100 to 200-fold better transduction efficiency than soluble, completely or partially correctly folded protein.
  • the present invention can be used to enhance expression of vectors, proteins and/or assist in transduction of pharmacologically important peptidyl mimetics to target cells.
  • the present invention overcomes problems due to low percentage of cells targeted, overexpression, size constraints and bioavailability.
  • the invention provides an in-frame bacterial expression vector, pTAT, incorporating an N' terminal protein transduction domain from HIV TAT. Also provided is a purification protocol that yields energetically unstable, misfolded proteins capable of efficient transduction.
  • TAT fusion proteins from 15 to 115 kD were transduced into >99% of all target cells examined, including: peripheral blood lymphocytes, whole blood cells, bone marrow stem cells, diploid fibroblasts, fibrosarcoma cells, leukemic T-cells, osteocarcinoma cells, gliomas, murine 3T3 fibroblasts, hepatocarcinomas, macrophages and keratinocytes.
  • Transduction occurs in a concentration-dependent manner, achieving maximum intracellular concentrations in less than 30 minutes.
  • transduction of proteins directly into cells has broad potential in manipulation of experimental systems and in delivery of pharmacologically relevant proteins.
  • TAT fusion protein was purified on Ni- NTA in 8M urea as above in the examples above.
  • the denatured TAT fusion protein was injected onto a PD-10 Sephadex desalting column (Pharmacia) equilibrated in PBS. " The protein was separated from the urea by size exclusion. It was found that the denatured TAT fusion protein goes very rapidly from a denaturing environment (high concentration of urea) to an aqueous environment (relatively low concentration of urea). The result is that the TAT fusion protein becomes misfolded, present in a high ⁇ G state, and is fully soluble in aqueous solution. It is believed that rapid transition from the denaturing environment to the aqueous environment prevents formation of the normal (ie. native) structure, including alpha helices and ⁇ -pleated sheets.
  • the present rapid desalting method was easy to perform and could be practiced with a minimum investment of resources. It is believed that the method is generally applicable to most if not all fusion proteins.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention se rapporte à des méthodes particulièrement efficaces pour la transduction, à partir d'une molécule de fusion, d'une cellule souhaitée ou d'un groupe de cellules tel qu'un tissu ou un organe. Ladite méthode consiste à mal replier la particule de fusion et à mettre en contact ladite particule de fusion mal repliée avec la cellule en question dans des conditions permettant la transduction de la molécule de fusion en la cellule souhaitée.
PCT/US1999/009028 1998-04-28 1999-04-27 Methodes de transduction de molecules de fusion WO1999055899A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002330560A CA2330560A1 (fr) 1998-04-28 1999-04-27 Methodes de transduction de molecules de fusion
JP2000546042A JP2002512808A (ja) 1998-04-28 1999-04-27 融合タンパク質の形質導入法
EP99918838A EP1073763A4 (fr) 1998-04-28 1999-04-27 Methodes de transduction de molecules de fusion
AU36658/99A AU3665899A (en) 1998-04-28 1999-04-27 Methods for transducing fusion molecules
AU2003244303A AU2003244303A1 (en) 1998-04-28 2003-09-02 Methods for transducing fusion molecules

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8338098P 1998-04-28 1998-04-28
US60/083,380 1998-04-28

Publications (2)

Publication Number Publication Date
WO1999055899A1 true WO1999055899A1 (fr) 1999-11-04
WO1999055899A9 WO1999055899A9 (fr) 1999-12-16

Family

ID=22177935

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/009028 WO1999055899A1 (fr) 1998-04-28 1999-04-27 Methodes de transduction de molecules de fusion

Country Status (5)

Country Link
EP (1) EP1073763A4 (fr)
JP (1) JP2002512808A (fr)
AU (2) AU3665899A (fr)
CA (1) CA2330560A1 (fr)
WO (1) WO1999055899A1 (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034308A2 (fr) * 1998-12-10 2000-06-15 Washington University Systeme de transduction de proteines et methodes d'utilisation
EP1037911A1 (fr) * 1997-12-10 2000-09-27 Washington University Systeme anti-pathogene et procedes d'utilisation
WO2001049832A2 (fr) * 2000-01-07 2001-07-12 Artemis Pharmaceuticals Gmbh Transduction de recombinases pour ciblage genetique inductible
DE10212867A1 (de) * 2002-03-22 2003-10-23 Hans Wolf Verwendung Harnstoff-adjuvierter Polypeptide zur Diagnose, Prophylaxe und Therapie
US6881825B1 (en) 1999-09-01 2005-04-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Identication of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and virues
US7037889B2 (en) 2000-09-13 2006-05-02 Praecis Pharmaceuticals Inc. Pharmaceutical compositions for sustained drug delivery
US7183066B2 (en) 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
US7374896B2 (en) 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
US7399607B2 (en) 2004-09-22 2008-07-15 Allergan, Inc. Fluorescence polarization assays for determining clostridial toxin activity
WO2010115984A1 (fr) 2009-04-09 2010-10-14 Lophius Biosciences Gmbh Procédé de transfert de polypeptides dans des cellules
US7846722B2 (en) 2001-08-28 2010-12-07 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
EP2264458A1 (fr) 2005-04-05 2010-12-22 Allergan, Inc. Analyses de l'activité de la toxine clostridienne
US8003753B2 (en) 2001-08-28 2011-08-23 Allergan, Inc. Fret protease assays for clostridial toxins
US8318898B2 (en) * 2005-12-23 2012-11-27 Universite De Lausanne Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of cellular relaxation
WO2013165816A2 (fr) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. Compositions de petit acide nucléique interférent (sina)
EP3252068A2 (fr) 2009-10-12 2017-12-06 Larry J. Smith Procédés et compositions permettant de moduler l'expression génique à l'aide de médicaments à base d'oligonucléotides administrés in vivo ou in vitro

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4342900A (en) * 1999-04-12 2000-11-14 Modex Therapeutiques, S.A. Transiently immortalized cells for use in gene therapy
US6358739B1 (en) * 1999-04-12 2002-03-19 Modex Therapeutiques, S.A. Transiently immortalized cells
JP2002331695A (ja) * 2001-05-11 2002-11-19 Fuji Xerox Co Ltd インクジェットプリンタの印字システムおよびインクジェット記録方法とインクジェットプリンタ

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4999422A (en) * 1988-04-15 1991-03-12 Biogen, N.V. Continuous method of refolding proteins
US5652122A (en) * 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4999422A (en) * 1988-04-15 1991-03-12 Biogen, N.V. Continuous method of refolding proteins
US5652122A (en) * 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BONIFACI N., SITIA R., RUBARTELLI A.: "NUCLEAR TRANSLOCATION OF AN EXOGENOUS FUSION PROTEIN CONTAINING HIV TAT REQUIRES UNFOLDING.", AIDS, LONDON, GB, vol. 09., no. 09., 1 January 1995 (1995-01-01), GB, pages 995 - 1000., XP002913782, ISSN: 0269-9370 *
SAMBROOK J., FRITSCH E. F., MANIATIS T.: "MOLECULAR CLONING. LABORATORY MANUAL.", 1 January 1989, NEW YORK, COLD SPRING HARBOUR PRESS., US, article SAMBROOK J, FRITSCH E F, MANIATIS T: "PROTEIN PURIFICATION INCLUSION BODIES", pages: 7.37 - 7.41, XP002921767, 016612 *
See also references of EP1073763A4 *
STERNSON L A: "OBSTACLES TO POLYPEPTIDE DELIVERY", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK ACADEMY OF SCIENCES., US, vol. 507, 1 January 1987 (1987-01-01), US, pages 19 - 21, XP002921766, ISSN: 0077-8923, DOI: 10.1111/j.1749-6632.1987.tb45788.x *
VANDENBROECK K, ET AL.: "REFOLDING AND SINGLE-STEP PURIFICATION OF PORCINE INTERFERON-GAMMA FROM ESCHERICHIA COLI INCLUSION BODIES CONDITIONS FOR RECONSTITUTION OF DIMERIC IFN-GAMMA", EUROPEAN JOURNAL OF BIOCHEMISTRY, WILEY-BLACKWELL PUBLISHING LTD., GB, vol. 215, 1 January 1993 (1993-01-01), GB, pages 481 - 486, XP002921768, ISSN: 0014-2956, DOI: 10.1111/j.1432-1033.1993.tb18057.x *
VERNER K, SCHATZ G: "PROTEIN TRANSLOCATION ACROSS MEMBRANES", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 241, no. 4871, 9 September 1988 (1988-09-09), US, pages 1307 - 1313, XP002921769, ISSN: 0036-8075, DOI: 10.1126/science.2842866 *

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1037911A4 (fr) * 1997-12-10 2003-07-23 Univ Washington Systeme anti-pathogene et procedes d'utilisation
EP1037911A1 (fr) * 1997-12-10 2000-09-27 Washington University Systeme anti-pathogene et procedes d'utilisation
WO2000034308A3 (fr) * 1998-12-10 2000-10-19 Univ Washington Systeme de transduction de proteines et methodes d'utilisation
WO2000034308A2 (fr) * 1998-12-10 2000-06-15 Washington University Systeme de transduction de proteines et methodes d'utilisation
US6881825B1 (en) 1999-09-01 2005-04-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Identication of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and virues
WO2001049832A3 (fr) * 2000-01-07 2002-02-21 Artemis Pharmaceuticals Gmbh Transduction de recombinases pour ciblage genetique inductible
WO2001049832A2 (fr) * 2000-01-07 2001-07-12 Artemis Pharmaceuticals Gmbh Transduction de recombinases pour ciblage genetique inductible
US8084419B2 (en) 2000-09-13 2011-12-27 GlaxoSmithKline, LLC Pharmaceutical compositions for sustained drug delivery
US7037889B2 (en) 2000-09-13 2006-05-02 Praecis Pharmaceuticals Inc. Pharmaceutical compositions for sustained drug delivery
US7838260B2 (en) 2001-08-28 2010-11-23 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum toxin protease activity
US8053209B2 (en) 2001-08-28 2011-11-08 Allergan, Inc. FRET protease assays for clostridial toxins
US7374896B2 (en) 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
US8053208B2 (en) 2001-08-28 2011-11-08 Allergan, Inc. FRET protease assays for clostridial toxins
US8048643B2 (en) 2001-08-28 2011-11-01 Allergan, Inc. FRET protease assays for clostridial toxins
US8022172B2 (en) 2001-08-28 2011-09-20 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
US8013113B2 (en) 2001-08-28 2011-09-06 Allergan, Inc. FRET protease assays for clostridial toxins
US8003753B2 (en) 2001-08-28 2011-08-23 Allergan, Inc. Fret protease assays for clostridial toxins
US7846722B2 (en) 2001-08-28 2010-12-07 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
DE10212867B4 (de) * 2002-03-22 2005-07-21 Hans Prof. Dr. Wolf Verwendung Harnstoff-adjuvierter Polypeptide zur Diagnose, Prophylaxe und Therapie
DE10212867A1 (de) * 2002-03-22 2003-10-23 Hans Wolf Verwendung Harnstoff-adjuvierter Polypeptide zur Diagnose, Prophylaxe und Therapie
US7183066B2 (en) 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
US7749759B2 (en) 2002-09-27 2010-07-06 Allergan, Inc. Cell compositions useful for cell-based FRET assays for clostridial toxins
US7674601B2 (en) 2004-09-22 2010-03-09 Allergan, Inc. Fluorescence polarization assays for determining clostridial toxin activity
US7638294B2 (en) 2004-09-22 2009-12-29 Allergan, Inc. Fluorescence polarization assays for determining clostridial toxin activity
US7635574B2 (en) 2004-09-22 2009-12-22 Allergan, Inc. Fluorescence polarization assays for determining clostridial toxin activity
US7632655B2 (en) 2004-09-22 2009-12-15 Allergan, Inc. Fluorescence polarization assays for determining clostridial toxin activity
US7399607B2 (en) 2004-09-22 2008-07-15 Allergan, Inc. Fluorescence polarization assays for determining clostridial toxin activity
EP2264458A1 (fr) 2005-04-05 2010-12-22 Allergan, Inc. Analyses de l'activité de la toxine clostridienne
US8318898B2 (en) * 2005-12-23 2012-11-27 Universite De Lausanne Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of cellular relaxation
WO2010115984A1 (fr) 2009-04-09 2010-10-14 Lophius Biosciences Gmbh Procédé de transfert de polypeptides dans des cellules
EP3252068A2 (fr) 2009-10-12 2017-12-06 Larry J. Smith Procédés et compositions permettant de moduler l'expression génique à l'aide de médicaments à base d'oligonucléotides administrés in vivo ou in vitro
EP4089169A1 (fr) 2009-10-12 2022-11-16 Larry J. Smith Procédés et compositions permettant de moduler l'expression génique à l'aide de médicaments à base d'oligonucléotides administrés in vivo ou in vitro
WO2013165816A2 (fr) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. Compositions de petit acide nucléique interférent (sina)
EP3919620A1 (fr) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Compositions d'acide nucléique interférent court (sina)

Also Published As

Publication number Publication date
WO1999055899A9 (fr) 1999-12-16
EP1073763A4 (fr) 2002-08-07
CA2330560A1 (fr) 1999-11-04
AU3665899A (en) 1999-11-16
EP1073763A1 (fr) 2001-02-07
JP2002512808A (ja) 2002-05-08
AU2003244303A1 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
WO1999055899A1 (fr) Methodes de transduction de molecules de fusion
Becker-Hapak et al. TAT-mediated protein transduction into mammalian cells
JP4188909B2 (ja) 細胞質残留性細胞膜透過ペプチド及びこれの用途｛ＣｙｔｏｐｌａｓｍｉｃＴｒａｎｓｄｕｃｔｉｏｎＰｅｐｔｉｄｅｓａｎｄＵｓｅｓｔｈｅｒｅｏｆ｝
Ayers et al. Introduction of unnatural amino acids into proteins using expressed protein ligation
EP1991560B1 (fr) Peptide présentant une activité de pénétration de membrane cellulaire
Moroianu et al. The binding site of karyopherin alpha for karyopherin beta overlaps with a nuclear localization sequence.
Chou et al. Hepatitis delta antigen mediates the nuclear import of hepatitis delta virus RNA
Vocero-Akbani et al. Transduction of full-length Tat fusion proteins directly into mammalian cells: analysis of T cell receptor activation-induced cell death
JP2019533999A (ja) 直交（ｏｒｔｈｏｇｏｎａｌ）用途の古細菌ピロリジルｔＲＮＡ合成酵素
Vocero-Akbani et al. Protein transduction: delivery of Tat-GTPase fusion proteins into mammalian cells
JP6967002B2 (ja) トランスグルタミナーゼ認識部位を有するｆｋｂｐドメイン
US20030134352A1 (en) Facilitating protein folding and solubility by use of peptide extensions
JP2022549057A (ja) 分子の細胞内送達のための複合体
US6395875B1 (en) Recombinant soluble adenovirus receptor
Becker‐Hapak et al. Protein Transduction: Generation of Full‐Length Transducible Proteins Using the TAT System
JPH02152990A (ja) 細胞接着活性ポリペプチド
JPH01180900A (ja) 細胞接着活性ポリペプチド
KR100843634B1 (ko) 세포막투과 전달 펩타이드 및 이를 포함하는 생물제제
JPH03259084A (ja) トロンビン結合性物質の製造法
RU2802488C1 (ru) Белковая конструкция на основе рецептор-специфичного мутантного варианта противоопухолевого цитокина TRAIL в виде гибридного белка с пептидом, специфичным к интегрину αvβ3, для терапии солидных опухолей
WO2002085305A2 (fr) Compositions et methodes pouvant induire la mort de cellules cancereuses
JP4721564B2 (ja) ヒト細胞膜結合蛋白
EP2386570B1 (fr) Protéine de fusion de mélusine recombinante en tant qu'agent pharmacologique pour le traitement des pathologies cardiaques et compositions associées
Manoharan et al. High-level production and purification of biologically active proteins from bacterial and mammalian cells using the tandem pGFLEX expression system
JP2010071744A (ja) 化合物のスクリーニング方法、並びに、スクリーニング用キット

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/11-11/11, DRAWINGS, REPLACED BY NEW PAGES 1/11-11/11; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: KR

ENP Entry into the national phase

Ref document number: 2000 546042

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2330560

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 36658/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999918838

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999918838

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999918838

Country of ref document: EP